Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model. The medical technology firm on June 12,...
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagn...
Vivos Therapeutics (NASDAQ:VVOS) announced a strategic marketing and distribution alliance with a multi-center sleep testing and treatment operator in Colorado. In a statement, Vivos said that the all...
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit...
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executiv...
Vivos Therapeutics (NASDAQ:VVOS) told investors it continues to anticipate becoming cash flow positive from operations by the end of 2024 or the first quarter of 2025 as it successfully executes its c...
Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives...
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the devel...
Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured M...
Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured M...
Vivos Therapeutics (NASDAQ:VVOS) announced that its CARE oral medical devices for obstructive sleep apnea (OSA) have been approved for Medicare reimbursement. The company said this milestone achieveme...